Skip to main content
. 2018 Dec 30;11(1):9. doi: 10.3390/pharmaceutics11010009

Figure 5.

Figure 5

Simulations of intravitreal sustained release systems of bevacizumab (A), ranibizumab (B), rituximab (C), conbercept (D), and aflibercept (E). Simulated protein drug concentrations in the vitreous (solid lines) and aqueous humor (dashed lines) are shown. Simulations show intravitreal bolus injection (blue lines), and sustained delivery for 3 months (orange lines), 6 months (grey lines) and 12 months (yellow lines).